BOTOX瘦面针优惠价钱｜打BOTOX去皱效果｜MIOGGI

 

主页 > 医学美容 > 轮廓塑形 >

BOTOX® 瘦面紧致去皱

BOTOX®保妥適的英文全名是 Botulinum Toxin Type A，它是一種由桿菌素提煉而成的天然純化蛋白質，可作神經傳導阻斷劑使用。BOTOX®具有放鬆肌肉的功效，MIOGGI採用定點定量注術，可令過度活躍的肌肉得以放鬆，從而改善眉間、額頭、眼尾、鼻翼、唇周紋等動態皺紋。除此之外，BOTOX® 亦可達到瘦面、瘦小腿、瘦斜方肌等功效，更有效改善腋下、手掌或腳掌多汗症問題，視乎部位，療效可維持約6-12個月¹

甚麽是
BOTOX® 瘦面紧緻去皱疗程？
BOTOX 主要成分为肉毒杆菌素A型(Botulinum Toxin Type A)，是一种高度纯化的蛋白质，主要用于瘦面、淡纹、瘦小腿、止汗、提升面部轮廓及放松斜方肌。

BOTOX® 肉毒杆菌素是如何运作？
透过注射BOTOX 肉毒杆菌素，阻隔神经末梢讯息传递，有效放松并抚平动态纹、自然瘦面等显着效果。

为甚麽选择BOTOX® 肉毒杆菌素？

BOTOX® 肉毒杆菌素特点

真实个案

官方认证 原厂正货

BOTOX肉毒杆菌疗程效果能维持多久？

BOTOX肉毒杆菌疗程能维持达6个月18，客人可根据自己的情况或需要而接受下一次疗程。

我想接受BOTOX肉毒杆菌疗程，但我听说它是由毒素製成的，它是否安全？

BOTOX肉毒杆菌疗程是一种在严格监控下製造而成的高度纯化蛋白质#，其全球临床经验长达30年，并获美国FDA认证^，安全性在国际受到充分评估。

若长期使用BOTOX肉毒杆菌疗程，剂量会一次比一次提高吗？

不会，专业医生每次会依疗程部位与肌肉收缩强度而决定所需剂量，临床研究显示，BOTOX肉毒杆菌疗程会随着疗程次数的增加而延长效果的持续期，所以持续使用可逐渐减少疗程的次数17。

会造成脸部肌肉僵硬？脸部肌肉会否受损吗？

BOTOX肉毒杆菌疗程只针对疗程部位产生作用，针对性放松过于活跃的面部肌肉以达至去皱效果#，正确使用下并不会引起面部僵硬及构成伤害。

BOTOX肉毒杆菌疗程可与透明质酸一起使用吗？

可以。同时使用可以达致更理想的效果。举例来说，若眉心纹形成已久并出现静态纹，建议先接受BOTOX肉毒杆菌疗程使肌肉放松#，再接受透明质酸疗程来修饰静态纹，恢復平滑肌肤。

‡: Medical Insight, Inc 2022. Cosmetic Neurotoxin Market Study. January 2022. Based on worldwide neurotoxins 2021 (in sales value). #: BOTOX® Prescribing Information. HK-41906. May 2013. : Allergan Aesthetics. Data on File. REF-119535. Total number of BOTOX vials shipped as of 5 December 2022.^: U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter SUPPL-5303, October 2, 2017.References: 1. Trindade de Almeida A et al. Dermatol Surg 2015; 41: S19-S28. 2. Yu W et al. J Cosmet Laser Ther. 2018Oct;20(5):278-286. 3. U.S. Food and Drug Administration, Department of Health & Human Services. Botox approval letter 85-0226 & 85-0227, December 29, 1989. 4. Allergan. Unpublished Data. INT-BCT-2050129 – Worldwide BOTOX® marketing authorization status. October 2020. 5. Allergan. Unpublished Data. REF-100250. BOTOX® number of peer-reviewed articles vs competitors. August 2022. 6. Michaud T, et al. J Cosmet Dermatol. 2015;14(1):9–21. 7. DasGupta BR. Structures of botulinum neurotoxin, its functional domains, and perspectives on the crystalline type A toxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Decker, Inc; 1994: 15-39. 8. Coffield JA, Considine RV, Simpson LL. The site and mechanism of action of botulinum neurotoxin. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:3-13. 9. Schantz EJ, Johnson EA. Preparation and characterization of botulinum toxin type A for human treatment. In: Jankovic J, Hallet, M., ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:41-49. 10. Simpson LL. The actions of clostridial toxins on storage and release of neurotransmitters. In: Harvey AL, ed. Natural and Synthetic Neurotoxins (Neuroscience Perspectives). San Diego, CA: Academic Press; 1993:278-317. 11. Black JD, Dolly JO. Interaction of 125I-labeled botulinum neurotoxins with nerve terminals II. Autoradiographic evidence for its uptake into motor nerves by acceptor-mediated endocytosis. J Cell Biol. 1986;103(2):535-544. 12. Lebeda FJ, Hack DC, Bentry MK. Theoretical analyses of the functional regions of the heavy chain of botulinum neurotoxin. In: Jankovic J, Hallet M, ed. Therapy with Botulinum Toxin. New York, NY: Marcel Dekker, Inc; 1994:51-61. 13. Harvey AL. Presynaptic toxins. In: Smythies JR, Bradley RJ, ed. International Review of. 14. Neurobiology. San Diego, CA: Academic Press; 1990:201-239. 15. Tremaine AM, McCullough JL. Clin Cosmet Investig Dermatol. 2010;3:15–23. 16. Stotland MA et al. Plast Reconstr Surg 2007; 120(5):1386-9. 17. Beer KR et al. J Drugs Dermatol 2011;10:39-41. 18. De Boulle K et al. Dermatol Surg. 2018;44[11]:1437-1448. 19. De Maio M, et al. Plast Reconstr Surg. 2017 Aug;140(2):265e-276e. 20. Juvéderm® (Hyaluronic Acid Gel with Lidocaine) product series includes VOLUX™ (HKMD-190341), VOLUMA® (HKMD-100411), VOLIFT® (HKMD-130324), VOLBELLA® (HKMD-210451) and VOLITE™ (HKMD-180040).